STAAR Surgical (NASDAQ:STAA) Releases Earnings Results, Beats Expectations By $0.07 EPS

by · The Cerbat Gem

STAAR Surgical (NASDAQ:STAA – Get Free Report) issued its quarterly earnings data on Wednesday. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.07, FiscalAI reports. The firm had revenue of $93.52 million for the quarter, compared to analyst estimates of $78.72 million. STAAR Surgical had a negative net margin of 33.60% and a negative return on equity of 10.03%. STAAR Surgical’s revenue was up 119.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.10) EPS.

Here are the key takeaways from STAAR Surgical’s conference call:

  • STAAR reported a strong Q1 2026 with net sales of $93.5 million, up 119.6% year over year, and adjusted EBITDA swung to a $24.4 million profit from a $26.3 million loss last year.
  • China drove the quarter, with $47.4 million in sales, early demand for EVO+ ICL, and distributor inventory back within targeted levels, which management said makes the quarter a cleaner base going forward.
  • The company said it is seeing operating leverage and margin improvement, with gross margin rising to 73.6% and operating expenses down 18% excluding special items, while still targeting $225 million in full-year 2026 spending.
  • STAAR highlighted several growth catalysts, including FDA approval expanding EVO ICL to patients ages 45 to 60, continued U.S. momentum with sales above $6 million, and the global milestone of more than 4 million ICLs sold.
  • Management remained cautious on guidance, declining to endorse consensus or give specific Q2/Q3 forecasts because of macro, geopolitical, and seasonal uncertainty, even though it said Q2 appears to be shaping up normally.

STAAR Surgical Stock Performance

STAA stock traded up $2.94 during mid-day trading on Thursday, reaching $32.34. The company had a trading volume of 942,367 shares, compared to its average volume of 1,363,385. The firm has a fifty day simple moving average of $22.22 and a 200 day simple moving average of $22.54. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -19.46 and a beta of 1.20. STAAR Surgical has a fifty-two week low of $15.59 and a fifty-two week high of $35.87.

Insider Activity at STAAR Surgical

In other news, Director Broadwood Partners, L.P. bought 316,017 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were purchased at an average cost of $18.61 per share, for a total transaction of $5,881,076.37. Following the completion of the purchase, the director owned 16,123,842 shares of the company’s stock, valued at approximately $300,064,699.62. This represents a 2.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders bought 670,213 shares of company stock worth $12,266,249 over the last three months. Insiders own 39.90% of the company’s stock.

Hedge Funds Weigh In On STAAR Surgical

A number of institutional investors and hedge funds have recently modified their holdings of STAA. Caitong International Asset Management Co. Ltd raised its stake in STAAR Surgical by 2,605.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 1,016 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in STAAR Surgical by 375.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 4,673 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of STAAR Surgical by 9,928.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier’s stock worth $121,000 after buying an additional 4,468 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in shares of STAAR Surgical in the 3rd quarter valued at $208,000. Finally, Amundi purchased a new position in shares of STAAR Surgical in the 3rd quarter valued at $251,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Morgan Stanley initiated coverage on shares of STAAR Surgical in a report on Friday, January 16th. They issued an “underweight” rating and a $13.00 price objective on the stock. Piper Sandler restated a “neutral” rating and set a $33.00 price target on shares of STAAR Surgical in a research note on Thursday. Mizuho raised their price target on STAAR Surgical from $22.00 to $27.00 and gave the stock a “neutral” rating in a research report on Thursday. Canaccord Genuity Group set a $32.00 price objective on STAAR Surgical in a research note on Thursday. Finally, Wedbush upgraded STAAR Surgical from a “neutral” rating to an “outperform” rating and raised their target price for the company from $26.00 to $40.00 in a report on Thursday. Three analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $26.69.

View Our Latest Analysis on STAAR Surgical

Key Stories Impacting STAAR Surgical

Here are the key news stories impacting STAAR Surgical this week:

  • Positive Sentiment: STAAR Surgical reported first-quarter results that beat Wall Street expectations, with EPS of $0.10 versus $0.03 expected and revenue of $93.52 million versus $78.72 million expected. The company also posted 119.6% year-over-year revenue growth, highlighting a sharp operational rebound.
  • Positive Sentiment: Wedbush upgraded STAAR Surgical from neutral to outperform and set a $40 price target, implying meaningful upside from current levels. Wedbush upgrade on STAAR Surgical
  • Positive Sentiment: The company said it delivered record first-quarter sales and profitability, reinforcing the view that momentum is improving after a weaker prior period. STAAR Surgical reports record Q1 sales and profitability
  • Neutral Sentiment: Needham maintained a hold rating, saying trends look stable but visibility into the 2026 outlook remains limited. Needham maintains hold on STAAR Surgical
  • Neutral Sentiment: Mizuho raised its price target from $22 to $27 but kept a neutral rating, suggesting the stock may have run ahead of that view. Mizuho raises price target on STAAR Surgical

STAAR Surgical Company Profile

(Get Free Report)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.

Featured Articles